Cytokinetics (CYTK)

$66.62 +0.36 (0.54%)
Market Cap 8.10B
Revenue (ttm) 18.47M
Net Income (ttm) -589.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,191.82%
Debt to Equity Ratio -0.38
Volume 1,126,600
Avg Vol 1,908,586
Day's Range N/A - N/A
Shares Out 122.27M
Stochastic %K 79%
Beta 0.54
Analysts Strong Sell
Price Target $89.94

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
sanmateomaverick
sanmateomaverick Feb. 17 at 8:25 PM
$CYTK https://www.bitget.com/amp/news/detail/12560605203615
0 · Reply
armedgemini
armedgemini Feb. 13 at 4:29 AM
$CYTK It seems like every dip in the upper $50's is immediately bought. It appears some smart people are expecting the results that will be released in the next few months wioo be positive. I am hoping market turns really red to be able to buy call options if it gets into the $50's again.
0 · Reply
Daniech0514
Daniech0514 Feb. 12 at 4:40 AM
$CYTK i am no chart expert but i am pretty sure that's a pretty one :)
0 · Reply
biochirp
biochirp Feb. 11 at 9:32 PM
$CYTK should be triple digits
0 · Reply
MUHL
MUHL Feb. 11 at 8:13 PM
$CYTK damn no one’s yapping about this. Loaded up
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 11:40 PM
$CYTK Share Price: $63.35 Contract Selected: May 15, 2026 $65 Calls Buy Zone: $11.73 – $14.49 Target Zone: $19.32 – $23.62 Potential Upside: 56% ROI Time to Expiration: 94 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Feb. 9 at 2:20 PM
Piper Sandler reiterated Best Idea $EWTX at Overweight-$51 and said, Addressing 30 Investor Questions on EWTX's Cardio Franchise $CYTK $BMY $CAPR $SLDB DYN SRPT PTCT Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2020864730361897007?s=20
1 · Reply
kareem1988
kareem1988 Feb. 9 at 11:29 AM
$VNDA $CYTK $IONQ $DRTS Social sentiment is hitting a fever pitch on these tickers. Here is why they are primed to dominate this week: $DRTS : Chatter is spiking. With technical leadership now in the U.S. and modular FDA submissions moving, the transition from R&D to global commercial player is happening in real-time. and lets not forget Japan PMDA decision for head & neck cancer enters the "imminent" window. $VNDA : Social volume is surging ahead of the Feb 21 PDUFA. Traders are piling in early to front-run the FDA’s decision on Bysanti. Expect high volatility and "buy the rumor" momentum all week. $CYTK : Trending heavily after Truist named it a top 2026 pick. Investors are laser-focused on the Aficamten launch and its potential to disrupt the cardiac market. The "moment of truth" is nearing. $IONQ : Leading the quantum conversation on social. After breaking through key technical resistance, retail is hyped on its DARPA and NVIDIA partnerships.
0 · Reply
MomentumInvestments
MomentumInvestments Feb. 4 at 11:55 AM
$CYTK is a biotech with a novel cardiac myosin inhibitor for heart failure; its commercial launch trajectory is critical to justify its premium valuation.
2 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 8:23 PM
$CYTK Current Stock Price: $64.93 Contracts to trade: $65.0 CYTK Feb 20 2026 Call Entry: $3.70 Exit: $6.64 ROI: 80% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on CYTK
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb 17, 2026, 7:30 AM EST - 11 hours ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Feb 12, 2026, 4:00 PM EST - 5 days ago

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Feb 9, 2026, 7:30 AM EST - 8 days ago

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Jan 27, 2026, 7:30 AM EST - 21 days ago

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Jan 22, 2026, 2:39 PM EST - 26 days ago

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 20, 2026, 4:00 PM EST - 4 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:46 PM EST - 5 weeks ago

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:00 PM EST - 6 weeks ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics: Small Label Differences With Big Commercial Stakes

Dec 22, 2025, 5:33 PM EST - 2 months ago

Cytokinetics: Small Label Differences With Big Commercial Stakes

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Dec 22, 2025, 11:23 AM EST - 2 months ago

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Dec 22, 2025, 9:47 AM EST - 2 months ago

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:08 PM EST - 2 months ago

US FDA approves Cytokinetics' heart disease drug

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 19, 2025, 4:00 PM EST - 2 months ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 17, 2025, 7:30 AM EST - 2 months ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 16, 2025, 4:00 PM EST - 2 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 2 months ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 2 months ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB TVTX XBI

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Nov 19, 2025, 7:40 AM EST - 3 months ago

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Nov 17, 2025, 8:10 AM EST - 3 months ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 12, 2025, 7:28 PM EST - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 10, 2025, 6:16 PM EST - 3 months ago

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Nov 10, 2025, 7:30 AM EST - 3 months ago

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 7, 2025, 10:01 AM EST - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:46 AM EST - 3 months ago

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:00 PM EST - 3 months ago

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics to Participate in November Investor Conferences

Nov 4, 2025, 4:00 PM EST - 3 months ago

Cytokinetics to Participate in November Investor Conferences

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Oct 31, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Oct 28, 2025, 4:32 PM EDT - 4 months ago

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Oct 28, 2025, 3:08 PM EDT - 4 months ago

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Oct 23, 2025, 1:37 PM EDT - 4 months ago

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Oct 22, 2025, 4:00 PM EDT - 4 months ago

Cytokinetics to Announce Third Quarter Results on November 5, 2025

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Oct 7, 2025, 7:58 AM EDT - 4 months ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Sep 29, 2025, 4:21 PM EDT - 5 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Sep 29, 2025, 7:30 AM EDT - 5 months ago

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

sanmateomaverick
sanmateomaverick Feb. 17 at 8:25 PM
$CYTK https://www.bitget.com/amp/news/detail/12560605203615
0 · Reply
armedgemini
armedgemini Feb. 13 at 4:29 AM
$CYTK It seems like every dip in the upper $50's is immediately bought. It appears some smart people are expecting the results that will be released in the next few months wioo be positive. I am hoping market turns really red to be able to buy call options if it gets into the $50's again.
0 · Reply
Daniech0514
Daniech0514 Feb. 12 at 4:40 AM
$CYTK i am no chart expert but i am pretty sure that's a pretty one :)
0 · Reply
biochirp
biochirp Feb. 11 at 9:32 PM
$CYTK should be triple digits
0 · Reply
MUHL
MUHL Feb. 11 at 8:13 PM
$CYTK damn no one’s yapping about this. Loaded up
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 11:40 PM
$CYTK Share Price: $63.35 Contract Selected: May 15, 2026 $65 Calls Buy Zone: $11.73 – $14.49 Target Zone: $19.32 – $23.62 Potential Upside: 56% ROI Time to Expiration: 94 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Feb. 9 at 2:20 PM
Piper Sandler reiterated Best Idea $EWTX at Overweight-$51 and said, Addressing 30 Investor Questions on EWTX's Cardio Franchise $CYTK $BMY $CAPR $SLDB DYN SRPT PTCT Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2020864730361897007?s=20
1 · Reply
kareem1988
kareem1988 Feb. 9 at 11:29 AM
$VNDA $CYTK $IONQ $DRTS Social sentiment is hitting a fever pitch on these tickers. Here is why they are primed to dominate this week: $DRTS : Chatter is spiking. With technical leadership now in the U.S. and modular FDA submissions moving, the transition from R&D to global commercial player is happening in real-time. and lets not forget Japan PMDA decision for head & neck cancer enters the "imminent" window. $VNDA : Social volume is surging ahead of the Feb 21 PDUFA. Traders are piling in early to front-run the FDA’s decision on Bysanti. Expect high volatility and "buy the rumor" momentum all week. $CYTK : Trending heavily after Truist named it a top 2026 pick. Investors are laser-focused on the Aficamten launch and its potential to disrupt the cardiac market. The "moment of truth" is nearing. $IONQ : Leading the quantum conversation on social. After breaking through key technical resistance, retail is hyped on its DARPA and NVIDIA partnerships.
0 · Reply
MomentumInvestments
MomentumInvestments Feb. 4 at 11:55 AM
$CYTK is a biotech with a novel cardiac myosin inhibitor for heart failure; its commercial launch trajectory is critical to justify its premium valuation.
2 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 8:23 PM
$CYTK Current Stock Price: $64.93 Contracts to trade: $65.0 CYTK Feb 20 2026 Call Entry: $3.70 Exit: $6.64 ROI: 80% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Feb. 3 at 5:51 PM
$CYTK Buying Opportunity Truist Securities raises target price to $92 from $84
0 · Reply
erevnon
erevnon Feb. 3 at 1:45 PM
Truist Securities maintains Cytokinetics $CYTK at Buy and raises the price target from $84 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 3 at 12:55 AM
The attached table notes the day of the week all 82 commercial-stage oncology (26) & non-oncology (56) bio M&A transactions were announced (those bios with 1st FDA approvals since 1/1/2013 so you won't see SGEN nor CELG for example). Roughly half of these M&A exits are announced on Mondays. In oncology its 62% of the time. Wednesday is the next most popular day of the week to announce acquisitions in this peer group. We track the dates M&A transactions are announced manually & use the "WEEKDAY" tool in excel to extrapolate the day of the week. In the past, we misread the "WEEKDAY" result by assuming 2 represented Tuesdays. Hence until we re-ran this analysis we thought Tuesdays were the most popular day to announce M&A trxs. We're going to run the same for clinical-stage bio M&A exits in the next few days. Our educated guesses of strong M&A candidates include: $SNDX $ARWR $CYTK $VKTX $XERS This is not investment advice. We're only sharing our analysis for entertainment purposes only.
0 · Reply
timfris
timfris Jan. 29 at 10:46 PM
$VKTX I’ve waited our $CYTK, $BBIO, and even $AUPH, this will be worth it too.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 9:02 PM
$CYTK Share Price: $65.59 Contract Selected: May 15, 2026 $65 Calls Buy Zone: $12.58 – $15.54 Target Zone: $21.23 – $25.95 Potential Upside: 59% ROI Time to Expiration: 105 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
UsandThem7
UsandThem7 Jan. 29 at 6:42 PM
$CYTK it’s coming
0 · Reply
buyandsold
buyandsold Jan. 28 at 6:18 PM
$TRDA $CYTK green today deserves a rocket ship emoji
0 · Reply
Quantumup
Quantumup Jan. 28 at 1:22 PM
Barclays assumed coverage on $CYTK at an Overweight rating and an $87 PT. $BMY $EWTX Barclays said in its note: The Myqorzo launch kicked off today. Given a differentiated label with flexibility of titration, less Echo monitoring, and no DDI in Box Warning, we continue to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy (oHCM). Our deep dive supported high probability of a positive outcome for Myqorzo in a Ph3 ACACIA trial (data expected in 2Q26) in non-obstructive hypertrophic cardiomyopathy (nHCM) with dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%), supporting aficamten as the sole drug with both indications in HCM.
0 · Reply
Quantumup
Quantumup Jan. 27 at 7:55 PM
Truist reiterated $CYTK Buy-$84 and said, We remain buyers of CYTK following KOL feedback that recognizes Camzyos as a meaningful advance for HCM patients while indicating a tilt in clinical preference for MYQORZO, especially for new patient starts. $BMY $EWTX Truist added, While our earlier KOL checks were positive towards Camzyos (LINK1, LINK2, LINK3) as the sole approved CMI, we noted emerging signals that a differentiated label for aficamten could drive a preference. We think positive KOL sentiment supports our $3.7B WW peak sales est. (in-line w/ cons). Many KOLs believe beta-blockers will have a place in therapy, but that many will eventually progress to a CMIs. Virtual call w/ Dr. Masri on 2/3 at 10:00 am ET.
0 · Reply
biochirp
biochirp Jan. 27 at 3:34 PM
$CYTK 85 wen
0 · Reply
MUHL
MUHL Jan. 27 at 3:13 PM
$CYTK time to go
0 · Reply
MillionTrader_xy
MillionTrader_xy Jan. 27 at 6:58 AM
$RVMD is $CYTK 2.0 next step Offering
0 · Reply